- The efficacy and safety of taletrectinib in patients with TKI-naive or crizotinib-pretreated ROS1-positive non-small cell lung cancer (NSCLC).Li, Wei; Yang, Nong; Ma, HuiWen; Fan, Huijie; Li, Kunyan; Wu, Huijuan; Yu, Qitao; Wang, Yongsheng; Meng, Xue; Wang, Xicheng; Qin, Xintian; Wang, Ziping; Liu, Yunpeng; Tao, Min; Zhuang, Wu; Fang, Yong; Sun, Ping; Lu, Kaihua; Wu, Jingxun; Zhou, CaicunAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.被引 1
- Updated efficacy and safety of taletrectinib in patients ( pts) with ROS1+non-small cell lung cancer (NSCLC)Li, W.; Yang, N.; Li, K.; Fan, H.; Yu, Q.; Wu, H.; Wang, Y.; Meng, X.; Wu, J.; Wang, Z.; Liu, Y.; Wang, X.; Qin, X.; Lu, K.; Zhuang, W.; He, S.; Janne, P. A.; Seto, T.; Ou, S-H. I.; Zhou, C.
- A phase II study of SAF-189s in patients with advanced ROS1 fusion-positive non-small cell lung cancerYang, J.; Zhou, J.; Li, M.; Zhang, Z-Y.; Cheng, Y.; Chu, D. H.; Pan, H.; Wang, B.; Chen, G.; Wang, K.; Jiang, L.; Hu, Y.; Shi, J.; Hui, A-M.; Zhou, Y.; Wu, Z.; Sun, J.; Tan, Y.; Xiang, X.; Wu, Y-L.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.
会议论文
The efficacy and safety of TQ-B3101 monotherapy in the first-line treatment in patients with ROS1-positive non-small cell lung cancer
2被引16阅读
